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PreviewsHolding the line on hepatic fat
When chronically elevated, insulin increases hepatic lipogenesis and VLDL synthesis. However, the hormone reduces liver
lipids when acutely elevated. Work in this issue of Cell Metabolism (Najjar et al., 2005) suggests a new mechanism for the
inhibition of the rate-limiting enzyme in liver, fatty acid synthase.There is little doubt that insulin is the d
most potent anabolic agent known, and m
a particularly powerful lipogenic hor- a
mone. Knowing how sensitive the liver m
is to insulin and the high expression of s
lipogenic enzymes in this important or- s
gan, have you ever wondered why he- o
patic fat deposits don’t rise and fall like i
glucose levels? Have you questioned h
why even the nonobese among us don’t
suffer constantly from hepatic steatosis o
(fatty liver)? Have you stayed up nights p
pondering the molecular mechanisms i
that keep the lid on lipogenesis in the t
liver? A new report from Najjar et al.
g
(2005) sheds new light on this dilemma,
(suggesting that while chronically ele-
vated insulin increases fatty acid synthe-
sis, insulin also acutely decreases lipo-
genesis in the short term, thus keeping
hepatic fat under control.
Insulin promotes the synthesis and
storage of lipids and carbohydrates in
the liver and blocks their breakdown and
release into the circulation (Saltiel and
Kahn, 2001). This is accomplished by
acute catalytic regulation of metabolic
enzymes such as glycogen synthase
and pyruvate dehydrogenase (usually by
changes in phosphorylation), as well as
protracted changes in the expression of
genes encoding enzymes like phospho-
enolpyruvate carboxykinase (PEPCK), fatty
acid synthase (FAS), and acetyl-CoA car-
boxylase. Recent studies suggest that in-
creased lipogenic gene expression re-
quires activation of the transcription factor
steroid regulatory element binding protein
(SREBP)-1c. Dominant-negative forms of
SREBP-1 can block expression of the lipo-
genic genes, whereas overexpression can
increase their transcription (Shimomura
et al., 2000). Interestingly, hepatic SREBP
levels are increased in some rodent
models of lipodystrophy, and this is as-
sociated with increases in fatty acid syn- F
thesis, the exact phenotype observed in F
ogenetic models of obesity-induced dia-
cbetes. Thus, although insulin seems to
gincrease its activity, amplified expres-
e
sion of SREBP-1c might contribute to c
uthe insulin resistance observed in liver ofCELL METABOLISM : JULY 2005 · VOL. 2 · COPiabetic rodents. These observations t
ake it clear that in order to avoid fat p
ccumulation in the liver, FAS activity t
ust be maintained at lower levels, de- i
pite the high level of expression. In m
upport of this idea, hepatic triglyceride y
utput is rapidly blocked by insulin surges t
n refed people but not in those already e
yperinsulinemic (Zammit, 2002). c
What accounts for the acute inhibition p
f FAS? Najjar et al. (2005) have pro- p
osed a novel mechanism; a direct p
nteraction of FAS with the insulin recep- p
or substrate carcinoembryonic anti- C
en-related cell adhesion molecule 1 p
CEACAM1). CEACAM1 is a liver-specific the enzyme FAS. Further studies re-
igure 1. A hypothetical model for the acute inhibition of hepatic fatty acid synthase (FAS) by insulin
ollowing its activation by insulin, the insulin receptor can catalyze the tyrosine phosphorylation of a number
f intracellular substrates. One of these leads to activation of the transcription factor SREBP-1, which in-
reases the expression of lipogenic enzymes such as FAS. Another receptor substrate is the transmembrane
lycoprotein CEACAM1. Upon phosphorylation on tyrosine, both the insulin receptor and CEACAM1 undergo
ndocytosis. CEACAM1 can then interact with FAS in a phosphorylation-dependent manner and reduce the
atalytic activity of the enzyme. Thus, insulin can reduce hepatic lipogenesis in the short term and promote it
pon prolonged exposure.YRIGHT © 2005 ELSEVIER INC.ransmembrane glycoprotein that is
hosphorylated on a single tyrosine by
he insulin receptor and plays a role in
nsulin clearance by increasing receptor-
ediated endocytosis. Upon phosphor-
lation, CEACAM1 and the insulin recep-
or undergo internalization via classic
ndocytotic mechanisms in clathrin-
oated pits (Najjar, 2002). The role of the
rotein in insulin action was uncertain,
rompting Najjar et al. to perform GST
ulldown assays with phosphorylated
eptides from the intracellular tail of
EACAM1 to fish out interesting binding
roteins. Using this approach, they found1
P R E V I E Wvealed that once internalized, CEA- n
pCAM1 can bind to FAS, in the process
Clowering FAS activity (Figure 1). The
ibinding and inhibition were absolutely
tdependent on tyrosine phosphorylation
oof CEACAM1, thus explaining the effect
Tof insulin. In support of the model, dis-
cruption of the CEACAM1 gene or trans-
bgenic expression of a phosphorylation-
adeficient mutant in liver prevents the
yacute inhibitory effect of insulin and re-
wsults in elevated hepatic lipogenesis. In-
terestingly, since the expression of CEA-
bCAM1 is liver specific, this effect of
tinsulin is not seen in adipose tissue,
l
where lipogenesis is increased by insulin
i
in both the acute and chronic phases. l
The study raises a number of impor- I
tant questions, most of which focus on n
the mechanism of CEACAM1’s inhibitory m
actions on FAS. The first and most obvi- m
ous pertains to the stoichiometry of the l
interaction between these proteins. Since h
CEACAM1 is a relatively immobile trans- a
membrane protein that co-segregates i
with the insulin receptor, its tyrosine d
phosphorylation would not lead to sig m
qnificant amplification of the insulin sig-2al. In this light, FAS is likely to be ex- r
ressed at levels far greater than those of t
EACAM1. Moreover, the requirement for s
nternalization of CEACAM1 in endocy- a
otic vesicles to exert its inhibitory action h
n FAS makes the feat even more difficult.
hus, the fraction of FAS that undergoes A
atalytic inhibition by CEACAM1 needs to L
e clarified, as does the molecular mech- U
nism(s) by which this tyrosine phosphor- A
lated transmembrane protein interacts
Sith FAS and blocks its catalytic activity.
The specific blockade of FAS activity N
y CEACAM1 in liver may provide a clue 1
o understanding so-called “mixed insu- N
in resistance” that has been observed A
n a number of models of obesity and Q
Cipodystrophy (Shimomura et al., 2000).
n this scenario, insulin’s antigluconeoge- S
7ic and glycogenic actions are compro-
ised, whereas its lipogenic effects re- S
ain intact, and fat accumulates in the B
(iver. Although mutations in CEACAM1
ave not been found in patients with di- Z
betes or insulin resistance, it is tempt- 5
ng to speculate that CEACAM1-depen-
Dent inhibition of fatty acid synthesis
ight be compromised as a conse-
uence or even a cause of the insulin-esistant state. In this case, finding ways
o mimic the inhibitory effects of the tyro-
ine phosphorylated peptide might help to
lleviate chronically elevated plasma and
epatic lipidemia in diabetes.
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